Lv6
2480 积分 2022-05-09 加入
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
3个月前
已关闭
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
3个月前
已完结
Improving outcomes of patients with pancreatic cancer
7个月前
已完结
The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma
7个月前
已完结
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
7个月前
已完结
Targeting STING to generate therapeutic anti-tumor immunity
8个月前
已完结
Clinical subtypes of stage IV pancreatic ductal adenocarcinoma: a new perspective of clinical practices
8个月前
已关闭
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
10个月前
已完结
Recent advances in therapeutic targeting of the KRAS pathway in cancer
10个月前
已完结
Combinatorial strategies to target RAS-driven cancers
10个月前
已完结
皖公网安备34019202002308
